| This retrolective safety analysis of pharmacovigilance data covered 99.4% (1596/1606) of all AMPs marketed in Germany during the study period 2010–2017. |
| A total of 5506 ADRs were identified that had occurred in 2765 different patients, comprising 370 different AMPs. |
| The relative frequency of ADRs for AMPs was 1.5 per million maximum daily administration doses sold. |
| The large majority of patients (91.9%) had recovered or were recovering from the ADRs and there were no reports with a fatal outcome. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.